Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-03-21
DOI
10.3389/fimmu.2022.827921
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma
- (2021) Ming Yi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Regulation of PD-L1 expression in the tumor microenvironment
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
- (2021) Zi Yin et al. Journal for ImmunoTherapy of Cancer
- Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
- (2021) Heli Vajavaara et al. Cancers
- The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte
- (2021) Baojuan Han et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- Polymorphisms and Circulating Plasma Protein Levels of Immune Checkpoints (CTLA-4 and PD-1) Are Associated With Posner-Schlossman Syndrome in Southern Chinese
- (2021) Xiaosheng Huang et al. Frontiers in Immunology
- Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study
- (2021) Renate Pichler et al. Journal of Clinical Medicine
- Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma
- (2021) Gorka Larrinaga et al. Cancers
- The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
- (2021) Pei Huang et al. Frontiers in Oncology
- Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
- (2021) Mengke Niu et al. Experimental Hematology & Oncology
- Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer
- (2021) Yu Rebecca Miao et al. CLINICAL CANCER RESEARCH
- Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma
- (2021) Tudor Mocan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice
- (2021) Yandi Tan et al. International Journal of Nanomedicine
- Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives
- (2021) Pasquale Persico et al. Journal of Clinical Medicine
- Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A4
- (2021) Tianxin Lyu et al. Experimental Hematology & Oncology
- Non-cytomembrane PD-L1: An atypical target for cancer
- (2021) Honggang Ying et al. PHARMACOLOGICAL RESEARCH
- Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy
- (2021) Rong Fu et al. Cancer Management and Research
- Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
- (2021) Christian Bailly et al. Cancers
- High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
- (2021) Ulrich Krafft et al. Cancers
- Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics
- (2021) Abhimanyu Thakur et al. Bioactive Materials
- Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis
- (2021) Yang Cheng et al. Future Oncology
- Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
- (2021) Anna Pawłowska et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma
- (2021) Tadashi Shiraishi et al. ONCOLOGY
- Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
- (2021) Anders Vikerfors et al. Cancers
- The biology, function, and biomedical applications of exosomes
- (2020) Raghu Kalluri et al. SCIENCE
- Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
- (2020) Manuela Tiako Meyo et al. Cancers
- Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients
- (2020) Marine Cordonnier et al. Journal of Extracellular Vesicles
- Trophoblast‐secreted soluble‐PD‐L1 modulates macrophage polarization and function
- (2020) Yong‐Hong Zhang et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
- (2020) Gary Middleton et al. Lancet Respiratory Medicine
- Ultrasound-Mediated Co-Delivery of miR-34a and sPD-1 Complexed with Microbubbles for Synergistic Cancer Therapy
- (2020) Yu-e Qin et al. Cancer Management and Research
- Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy
- (2020) Ang Zhang et al. CYTOTHERAPY
- Predicting treatment response of patients with extranodal natural killer/T‐cell lymphoma based on levels of PD‐L1 mRNA and soluble PD‐L1
- (2020) Yu Feng et al. HEMATOLOGICAL ONCOLOGY
- Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas
- (2020) Kunihiro Asanuma et al. Scientific Reports
- Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients
- (2020) Jun Wang et al. JOURNAL OF NANOBIOTECHNOLOGY
- The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction
- (2020) Shiyu Li et al. INTERNATIONAL JOURNAL OF CANCER
- Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
- (2020) Muhammad Khan et al. Frontiers in Immunology
- The roles of exosomes in cancer drug resistance and its therapeutic application
- (2020) Shiyu Li et al. Clinical and Translational Medicine
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
- (2019) Benjamin Bian et al. OncoImmunology
- Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
- (2019) Tetsuro Tominaga et al. PLoS One
- Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
- (2019) Bo Gong et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway
- (2019) Rui Zhao et al. CELL PROLIFERATION
- Exosomes in cancer development, metastasis, and immunity
- (2019) Lin Zhang et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
- (2019) Mauro Poggio et al. CELL
- Analysis of Plasma EBV-DNA and Soluble Checkpoint Proteins in Nasopharyngeal Carcinoma Patients after Definitive Intensity-Modulated Radiotherapy
- (2019) Yanyun Ruan et al. Biomed Research International
- Exosomes
- (2019) D. Michiel Pegtel et al. Annual Review of Biochemistry
- Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma
- (2019) Beatrice M Razzo et al. CARCINOGENESIS
- Metalloproteinases at the surface of small extrcellular vesicles in advanced ovarian cancer: Relationships with ascites volume and peritoneal canceromatosis index
- (2019) Natalia V. Yunusova et al. CLINICA CHIMICA ACTA
- c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer
- (2019) Alexander Lux et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma
- (2019) Megumi Goto et al. Scientific Reports
- Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
- (2019) Robert Chen et al. BLOOD
- Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
- (2019) Dong Ha Kim et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Label-free and specific detection of soluble programmed death ligand-1 using a localized surface plasmon resonance biosensor based on excessively tilted fiber gratings
- (2019) Binbin Luo et al. Biomedical Optics Express
- Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
- (2019) Chuling Li et al. Journal of Translational Medicine
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- The role of exosomal PD-L1 in tumor progression and immunotherapy
- (2019) Feiting Xie et al. Molecular Cancer
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
- (2019) Shuang Qin et al. Molecular Cancer
- Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist
- (2019) Kevin W Ng et al. eLife
- Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells
- (2019) Yeni Romero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer
- (2018) Zehong Chen et al. CANCER SCIENCE
- Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth
- (2018) Yi Yang et al. CELL RESEARCH
- Exosomes and Ectosomes in Intercellular Communication
- (2018) Jacopo Meldolesi CURRENT BIOLOGY
- Tumor exosomes block dendritic cells maturation to decrease the T cell immune response
- (2018) Yongling Ning et al. IMMUNOLOGY LETTERS
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
- (2018) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcriptome reprogramming by cancer exosomes: identification of novel molecular targets in matrix and immune modulation
- (2018) Fatima Qadir et al. Molecular Cancer
- Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels
- (2018) LiJun Xu et al. Molecular Oncology
- Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
- (2018) Franz L. Ricklefs et al. Science Advances
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
- (2018) Boyang Chang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression
- (2018) Kathleen M. Mahoney et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Identification and characterization of an alternative cancer-derived PD-L1 splice variant
- (2018) Nadia B. Hassounah et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B
- (2018) Liang Zhou et al. JOURNAL OF VIRAL HEPATITIS
- Soluble immune checkpoints in cancer: production, function and biological significance
- (2018) Daqian Gu et al. Journal for ImmunoTherapy of Cancer
- A SERS microfluidic platform for targeting multiple soluble immune checkpoints
- (2018) K.Kamil Reza et al. BIOSENSORS & BIOELECTRONICS
- Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage
- (2017) Mayuko Hira-Miyazawa et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
- (2017) Lukasz Skalniak et al. Oncotarget
- High-affinity human PD-L1 variants attenuate the suppression of T cell activation
- (2017) Zhaoduan Liang et al. Oncotarget
- Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
- (2017) Jun Zhou et al. Cancer Immunology Research
- Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
- (2017) Greta Garrido et al. Frontiers in Pharmacology
- Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
- (2017) Stephan Kruger et al. OncoImmunology
- Upregulation of soluble B7-H3 in NSCLC-derived malignant pleural effusion: A potential diagnostic biomarker correlated with NSCLC staging
- (2016) Liwen Chen et al. CLINICA CHIMICA ACTA
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib
- (2016) Steffen Filskov Sorensen et al. LUNG CANCER
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Soluble B7-H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4/NF-κB pathway
- (2016) Chao Xie et al. Scientific Reports
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Glioma-derived extracellular vesicles selectively suppress immune responses
- (2015) Justin E. Hellwinkel et al. NEURO-ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways
- (2015) Cuiping Liu et al. ARTHRITIS RESEARCH & THERAPY
- Role of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients with cystic echinococcosis
- (2015) YANHUA LI et al. Experimental and Therapeutic Medicine
- STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients
- (2015) R. M. Srivastava et al. Cancer Immunology Research
- A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage
- (2015) Colette Dezutter-Dambuyant et al. OncoImmunology
- Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
- (2015) Sara Labiano et al. OncoImmunology
- EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
- (2015) Wenfeng Fang et al. Oncotarget
- Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?
- (2014) Frank J Ward et al. Immunotherapy
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma
- (2014) Hsiang-Yun Cheng et al. PLoS One
- Reconstructed Adeno-Associated Virus with the Extracellular Domain of Murine PD-1 Induces Antitumor Immunity
- (2013) Osama A.O. Elhag et al. Asian Pacific Journal of Cancer Prevention
- The soluble isoform of CTLA-4 as a regulator of T-cell responses
- (2013) Frank J. Ward et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Detection of quinupristin-dalfopristin resistance in methicillin-resistant Staphylococcus aureus in South India
- (2013) Selvaraj Stephen et al. Indian Journal of Pathology and Microbiology
- Increased PD-1 on CD4+CD28− T cell and soluble PD-1 ligand-1 in patients with T2DM: Association with atherosclerotic macrovascular diseases
- (2013) Bimin Shi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Adenovirus Expressing Both Thymidine Kinase and Soluble PD1 Enhances Antitumor Immunity by Strengthening CD8 T-cell Response
- (2013) Seung-Pil Shin et al. MOLECULAR THERAPY
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
- (2012) N. Patsoukis et al. Science Signaling
- Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma
- (2012) XIU-CHENG PAN et al. Oncology Letters
- Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
- (2011) X. Frigola et al. CLINICAL CANCER RESEARCH
- Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
- (2011) Yongjing Chen et al. CYTOKINE
- Soluble B7-H1: Differences in production between dendritic cells and T cells
- (2011) Xavier Frigola et al. IMMUNOLOGY LETTERS
- IFN- Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
- (2011) S. Terawaki et al. JOURNAL OF IMMUNOLOGY
- Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1
- (2011) Mi-Young Song et al. JOURNAL OF IMMUNOTHERAPY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- B7-H1 up-regulation impairs myeloid DC and correlates with disease progression in chronic HIV-1 infection
- (2008) Xicheng Wang et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum
- (2008) Guangbo Zhang et al. IMMUNOLOGY
- Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells
- (2008) L. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More